Strengths
- CB Insights lists Neuralink as a $9.65B unicorn.
- Company/public sources verify active product positioning for Neuralink.
- Public R&D, hiring or team signals indicate an active operating profile.
Diligence report
Neuralink
Neuralink Startup Diligence Report
Proceed only after clinical, regulatory, safety, manufacturing and financing diligence. Public sources validate active trials and a unicorn-list valuation, but not clinical outcomes, commercial pricing, reimbursement, cap table or adverse-event history beyond public study listings.
Company profile
Neuralink Startup Diligence Report
Neuralink appears eligible for this run as a still-private unicorn target based on the current CB Insights unicorn-list row and active public operating pages. Public evidence supports product/activity and selected demand/team signals, but core investment diligence remains unresolved because financials, cap table, retention, contracts, legal/compliance records and management materials are private.
- Website
- neuralink.com
- Sector
- Healthcare and life sciences / implantable brain-computer interfaces
- Geography
- United States; Fremont, South San Francisco, Austin and U.S. clinical sites
- Stage
- Private unicorn / clinical-stage neurotechnology medical-device company
- Known aliases
- Neuralink Corp, N1 Implant, R1 Robot, Telepathy
- Report version
- 1.0
- Timezone
- UTC
Executive summary
Risks
- Clinical and regulatory approval risk for an invasive implantable device
- No public revenue, reimbursement, margin or runway evidence despite high valuation
- Operational and reputational exposure from surgery, patient safety and hardware manufacturing complexity
Gaps
- Audited financials, ARR/bookings bridge, gross margin, cash, debt, burn and forecast model.
- Cap table, preferences, option pool, warrants/notes/debt and financing documents.
- Top customer/user/patient cohorts, revenue concentration, churn, NRR, contracts and reference calls.
- CAC, payback, channel mix, quota attainment, sales cycle and pipeline quality.
- Legal, regulatory, privacy/security, IP, insurance and material-contract schedules.
Risk register
R-005: Product, technical and roadmap execution risk
Public materials show active product/R&D work, but roadmap delivery, quality, reliability, safety, model costs or technical debt are not fully public.
Diligence request: Request roadmap, architecture review, reliability metrics, incident history and R&D budget.
R-001: Financial quality and valuation bridge are not public
Public evidence does not disclose audited financial statements, ARR/bookings bridge, gross margin, cash, burn, debt or forecast assumptions for Neuralink.
Diligence request: Request audited financials, monthly KPI pack, cash runway, budget-to-actuals and valuation bridge.
R-003: Customer concentration and retention quality are unverified
Public demand signals do not disclose top-account revenue, churn, renewals, NRR, cohorts or satisfaction.
Diligence request: Request cohorts, top-account contracts, churn/NRR, support metrics and references.
R-006: Legal, regulatory, privacy, IP and compliance exposure
Public sources are insufficient for litigation, regulatory, privacy/security, insurance, IP ownership and material-contract diligence.
Diligence request: Have counsel run docket, regulatory, privacy, security, insurance and IP diligence.
R-002: Cap table, preferences and financing terms are private
Headline valuation does not disclose ownership, liquidation preferences, option pool, debt, warrants or secondary terms.
Diligence request: Request fully diluted cap table and financing documents.
R-004: Competitive durability and pricing power require proof
Neuralink operates in a market with credible substitutes and incumbents; public positioning does not prove win rates or switching costs.
Diligence request: Request win/loss, pricing benchmarks, renewal uplift and customer interviews.
R-007: Management, hiring and key-person risk
Public team evidence does not provide complete management biographies, incentives, attrition, compensation or key-person dependencies.
Diligence request: Request org chart, bios, references, HRIS, compensation plans and attrition.
R-008: Operational dependency and supplier concentration risk
Public sources do not disclose critical supplier contracts, service dependencies, manufacturing capacity, payment partners, model providers or resilience obligations.
Diligence request: Request supplier list, contracts, SLAs, business-continuity plans and concentration analysis.
01Financial Information
Neuralink's public valuation/status is supported by CB Insights, but financial statements, cap table, cash/debt and valuation bridge are private.
I.A Annual and quarterly financial information for the past three years
not publicly verifiable confidence: low
Public research for Neuralink verifies headline status and selected signals, but not audited statements, management accounts, backlog, AR aging or gross profit.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-001 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| metric | public signal | verification status | diligence request |
|---|---|---|---|
| Headline valuation | $9.65B | verified from market database | Tie to financing docs |
| Revenue / ARR / bookings | not publicly disclosed as audited revenue | not_publicly_verifiable | Request audited financials and ARR bridge |
| Usage/customer signal | ClinicalTrials.gov lists Neuralink Corp as sponsor of the PRIME early feasibility study, estimated enrollment of 15, study start 2024-01-09, estimated study completion 2031-01 and no results posted. | partially_verified | Reconcile to paid revenue and margin |
I.B Financial Projections
partially verified confidence: medium
A public valuation and momentum signals exist for Neuralink; projections and valuation bridge require private records.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-001 remains open until private diligence closes the related evidence gap.
- R-002 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
I.C Capital Structure
not publicly verifiable confidence: low
Public sources name selected investors and valuation context, but cap table, preferences, debt, warrants and option pool are not public.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-002 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| stakeholder | public position | diligence caveat |
|---|---|---|
| Named investors | Craft Ventures; Founders Fund; VY Capital | Ownership, preferences and rights are private |
| Founders / employees | not fully public in fetched sources | Request founder equity, vesting and option pool |
| Debt / warrants / SAFEs | not publicly disclosed | Request debt, warrants, notes, SAFEs and off-balance-sheet obligations |
I.D Other financial information
not publicly verifiable confidence: low
Public financing history is incomplete beyond valuation anchor and selected public signals.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-001 remains open until private diligence closes the related evidence gap.
- R-002 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| date | event | lead participants | amount | post money | source |
|---|---|---|---|---|---|
| 2021-07-30 | Unicorn-list entry / valuation anchor | Craft Ventures; Founders Fund; VY Capital | not disclosed in CB row | $9.65B | CB Insights unicorn list |
| current diligence date | Round-by-round financing history | not publicly complete | not_publicly_verifiable | not_publicly_verifiable | request company financing ledger |
02Products
Neuralink has a public product suite; SKU-level economics and roadmap commitments remain private.
II.A Description of each product
partially verified confidence: medium
Neuralink's public product pages support an active product suite, while SKU economics, roadmap commitments and profitability remain private.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-001 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| product | audience | key features | source | verification status |
|---|---|---|---|---|
| N1 Implant | Trial participants with paralysis | Skull-mounted wireless rechargeable implant connected to electrode threads | SRC-003 | verified |
| R1 Robot | Clinical surgical teams | Robotic electrode-thread inserter for ultra-fine threads | SRC-003 | verified |
| Neuralink application / Telepathy BCI | Clinical trial participants | Decodes neural signals into computer or device actions | SRC-002 | partially_verified |
| Patient Registry and clinical trials | Prospective trial participants | Active device-control and speech-restoration trials; visual-prosthesis trial upcoming | SRC-006 | verified |
| offering | public price or signal | public evidence | verification status |
|---|---|---|---|
| Commercial device pricing | not publicly disclosed | No public price, reimbursement code, bill of materials, gross margin or procedure economics found | not_publicly_verifiable |
| Trial participation economics | not publicly disclosed | Public trial pages do not disclose patient cost, sponsor-paid cost or site economics | not_publicly_verifiable |
| Future reimbursement | not publicly disclosed | Coverage, coding and hospital economics require private market-access plan | not_publicly_verifiable |
03Customer Information
Neuralink has public demand signals, but concentration, renewal health and supplier concentration require private diligence.
III.A Top customers by application
partially verified confidence: medium
Public demand signals exist; they are not a substitute for top-customer ARR, contract terms, renewal status or references.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-003 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| name | use case | public evidence | source | verification status |
|---|---|---|---|---|
| Public clinical trial participants | Early feasibility / BCI use | Trial population and study design are public, but no revenue customers are disclosed | SRC-005 | partially_verified |
| Barrow Neurological Institute | Clinical study site | ClinicalTrials.gov lists Phoenix site as recruiting | SRC-005 | verified |
| University of Miami | Clinical study site | ClinicalTrials.gov lists Miami site as recruiting | SRC-005 | verified |
| Patient Registry | Future trial recruitment | Company says registry is open worldwide for current and future trials | SRC-006 | verified |
III.B Strategic relationships
partially verified confidence: medium
Public relationships are visible at screening depth, but revenue contribution, exclusivity and termination rights are private.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-001 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| partner | nature | public evidence | gap |
|---|---|---|---|
| FDA IDE | Regulatory authorization context | Company states IDE awarded May 2023; full correspondence not public | Contract terms, economics, exclusivity, SLA and termination rights require private diligence |
| Independent IRB and hospital site | Trial recruitment gate | Company states IRB and first hospital site approval to begin recruitment | Contract terms, economics, exclusivity, SLA and termination rights require private diligence |
| Clinical trial sites | Study execution | ClinicalTrials.gov lists two U.S. study locations | Contract terms, economics, exclusivity, SLA and termination rights require private diligence |
III.C Revenue by customer
not publicly verifiable confidence: low
Revenue by customer and any customer over 5 percent of revenue are not public.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-003 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
III.D Significant relationships severed within the last two years
not publicly verifiable confidence: low
No public source reviewed disclosed severed material relationships in the last two years; absence of evidence is not confirmation.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-001 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
III.E Top suppliers
not publicly verifiable confidence: low
Critical supplier, platform, model, payment, clinical or infrastructure dependencies require private contract diligence.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-008 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| supplier or dependency | role | public evidence | concentration risk |
|---|---|---|---|
| Specialized implant components | Custom chips, hermetic enclosure, electrode threads | Supplier names and quality agreements are not public | Requires supplier concentration and contract diligence |
| Clinical sites / surgeons | Human implantation and follow-up | Contracts and capacity are private | Requires supplier concentration and contract diligence |
| Regulated manufacturing and quality systems | Medical-device production | ISO/FDA quality evidence requires private diligence | Requires supplier concentration and contract diligence |
04Competition
Neuralink competes in a crowded category where differentiation must be proven through win/loss and buyer references.
IV.A Competitive landscape by market segment
partially verified confidence: medium
Neuralink's public positioning supports a competitive map, but market share, win/loss and pricing power require buyer references.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-004 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| competitor | segment | product overlap | differentiator to test |
|---|---|---|---|
| Synchron | Endovascular BCI | Less-invasive BCI pathway | Validate safety, bandwidth and approval path |
| Precision Neuroscience | Cortical interface | Implant design and clinical pathway | Validate outcomes and manufacturability |
| Paradromics | High-data-rate BCI | Implantable neural interface | Validate bandwidth, safety and surgery workflow |
| Blackrock Neurotech | Neurotechnology devices | Established neurotechnology devices | Validate commercial approvals and clinical evidence |
| axis | target position | top competitor position | evidence or gap |
|---|---|---|---|
| Product breadth | N1 Implant; R1 Robot; Neuralink application / Telepathy BCI; Patient Registry and clinical trials | varies | Public product pages support breadth; usage by SKU private |
| Pricing power | not fully public | requires benchmark | Request discounting, win/loss and renewal uplift |
| Switching costs | inferred from workflow depth only | requires buyer interviews | Request churn, implementation time and references |
05Marketing, Sales, and Distribution
Neuralink's public GTM motions are visible, but source mix, CAC/payback and sales productivity are not public.
V.A Strategy and implementation
partially verified confidence: medium
Public GTM signals identify channels and messaging, but channel mix, CAC, payback, sales productivity and budget sufficiency are not public.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-004 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| channel | region | public evidence | gap |
|---|---|---|---|
| Clinical-trial recruitment | United States / registry | Trial and registry pages | Enrollment funnel, site capacity and adverse-event experience are private |
| Patient/caregiver awareness | Company website | Patient stories and trial links | Conversion and retention are not revenue proof |
| Medical-center partnerships | Clinical sites | ClinicalTrials.gov site listings | Contract terms and site economics private |
| signal | source | source id | diligence caveat |
|---|---|---|---|
| Unicorn valuation | CB Insights | SRC-001 | Not proof of current financial quality |
| Public product/customer messaging | Company pages | SRC-002 | Company-published and not independent cohort proof |
| Public usage/trial/customer signal | Public pages | SRC-003 | Needs reconciliation to paid retention and margin |
V.B Major Customers
partially verified confidence: medium
Major-customer trends and pipeline cannot be validated from public signals alone.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-003 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
V.C Principal avenues for generating new business
partially verified confidence: medium
Public sources indicate plausible acquisition motions, but source weights and conversion economics require pipeline data.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-004 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
V.D Sales force productivity model
not publicly verifiable confidence: low
Sales compensation, quota, sales cycle, ramp and productivity are private.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-001 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
V.E Ability to implement marketing plan with current and projected budgets
not publicly verifiable confidence: low
Marketing-plan budget sufficiency and implementation capacity require internal budget and staffing data.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-001 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
06Research and Development
Neuralink shows public R&D/product activity, while roadmap cost, quality, reliability and engineering metrics require private review.
VI.A Description of R&D organization
partially verified confidence: medium
Public sources show R&D/product activity, but org depth, quality systems, roadmap cost and technical debt are private.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-005 remains open until private diligence closes the related evidence gap.
- R-008 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| name or function | role | background or public signal | source |
|---|---|---|---|
| Clinical team | Clinical program execution | Company-level public trial contact; management roster not centralized | SRC-005 |
| Brain Interfaces roles | Neuroengineering and implant R&D | Careers page lists brain-interface and neuroengineering roles | SRC-007 |
| Surgery & Robotics roles | Robot, optics, firmware and surgical systems | Careers page lists surgery/robotics roles | SRC-007 |
| Quality & Preclinical roles | Quality systems, IACUC, preclinical studies | Careers page lists quality/preclinical roles | SRC-007 |
VI.B New Product Pipeline
partially verified confidence: medium
Public product/pipeline signals exist, while committed dates, development cost and reliability metrics require private diligence.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-005 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| project | status | public evidence | source | verification status |
|---|---|---|---|---|
| PRIME / device-control study | Active early feasibility | Estimated primary completion 2026-06 and study completion 2031-01 | SRC-005 | partially_verified |
| Speech-restoration trial | Active public company trial page | Trial page lists speech restoration as active | SRC-006 | partially_verified |
| Visual prosthesis trial | Upcoming | Trial page lists visual prosthesis as upcoming | SRC-006 | partially_verified |
07Management and Personnel
Neuralink's public team/hiring signals are incomplete; org chart, HRIS, compensation and turnover are private.
VII.A Organization Chart
not publicly verifiable confidence: low
A formal organization chart is not public.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-007 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
VII.B Historical and projected headcount by function and location
partially verified confidence: medium
Public hiring or function signals exist, but historical/projected headcount by function/location is not fully public.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-007 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| signal | public evidence | source | diligence need |
|---|---|---|---|
| Open-role categories | Brain Interfaces, Clinical, Surgery & Robotics, Quality, Software, Finance, Operations | SRC-007 | Public hiring signal |
| Locations | South San Francisco, Fremont, Austin and listed clinical sites | SRC-005; SRC-007 | Public location signal |
| Employee count / turnover | not publicly disclosed | not_publicly_verifiable | Requires HRIS and attrition data |
VII.C Senior management biographies
partially verified confidence: medium
Selected public leadership or function signals are available, but complete biographies and references require private diligence.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-007 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| name or role | public role | tenure or background | verification status |
|---|---|---|---|
| Executive leadership roster | Not centrally verified in fetched sources | Request officers, board minutes and management bios | not_publicly_verifiable |
| Clinical leadership | Study-site PI level visible, company executive level not complete | ClinicalTrials.gov lists site investigators; company management remains private | partially_verified |
| Functional leaders | Hiring categories imply functions, not named leaders | Careers page supports active hiring across functions | partially_verified |
VII.D Compensation arrangements
not publicly verifiable confidence: low
Employment agreements, compensation arrangements and benefit plans are private.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-007 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
VII.E Incentive stock plans
not publicly verifiable confidence: low
Equity incentive plan terms, option pool, refresh grants and vesting are private.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-007 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
VII.F Significant employee relations problems, past or present
not publicly verifiable confidence: low
Employee-relations problems are not assessable without HR, legal and employee-relations records.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-007 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
VII.G Personnel Turnover
not publicly verifiable confidence: low
Personnel turnover and retention data for the last two years are private.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-007 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
08Legal and Related Matters
Neuralink's public legal/regulatory/privacy signals are not sufficient for counsel-level diligence.
VIII.A Pending lawsuits against the Company
not publicly verifiable confidence: low
No comprehensive litigation-against-company docket search was included in public-source research.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-006 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| case | court or forum | filed date | status | source |
|---|---|---|---|---|
| No comprehensive public docket result included in this run | not_publicly_verifiable | not_publicly_verifiable | docket search required | counsel-led search request |
VIII.B Pending lawsuits initiated by Company
not publicly verifiable confidence: low
No comprehensive company-initiated litigation docket search was included in public-source research.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-006 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| defendant or matter | court or forum | filed date | status | source |
|---|---|---|---|---|
| No comprehensive initiated-by-company docket result included in this run | not_publicly_verifiable | not_publicly_verifiable | docket search required | counsel-led search request |
VIII.C Environmental and employee safety issues and liabilities
partially verified confidence: medium
Environmental, safety or workplace exposure diligence depends on company records and regulator correspondence.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-006 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
VIII.D Material patents, copyrights, licenses, and trademarks
partially verified confidence: medium
Material IP, licenses and assignments require a complete IP schedule and counsel review.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-006 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
| asset or matter | jurisdiction | status | source | diligence request |
|---|---|---|---|---|
| Public adverse-event litigation | United States | No comprehensive docket search artifact in this run | not_publicly_verifiable | Run counsel-led docket search |
| Investigational medical-device regulation | United States | FDA IDE and ClinicalTrials.gov record public | SRC-004; SRC-005 | Safety and IDE correspondence not public |
| IP / patents | United States | Material patent schedule not assembled in this run | not_publicly_verifiable | Request patent family schedule and FTO opinion |
| Privacy / patient data | United States | Privacy endpoint and trial context public | SRC-008 | HIPAA/GDPR/clinical data processing contracts require review |
VIII.E Insurance coverage and material exposures
not publicly verifiable confidence: low
Insurance coverage and material exposures are private.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-006 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
VIII.F Material contracts
not publicly verifiable confidence: low
Material contracts, change-of-control clauses and termination rights are private.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-006 remains open until private diligence closes the related evidence gap.
- R-008 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
VIII.G Regulatory agency problems
partially verified confidence: medium
Public legal/regulatory/privacy signals exist, but comprehensive regulatory correspondence and agency history require counsel-led diligence.
Evidence gaps
- Private records and direct counterparty confirmations are required to fully answer this checklist item.
Hidden risks
- R-006 remains open until private diligence closes the related evidence gap.
Follow-up questions
- Provide supporting private data-room documents for this checklist area.
Evidence
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | Neuralink is listed as a private unicorn at $9.65B. | verified high | SRC-001 |
| EC-002 | Neuralink publicly markets active products. | verified medium | SRC-002 |
| EC-003 | Neuralink has public monetization or financing signals, but complete financial statements are private. | partially verified medium | SRC-001SRC-005 |
| EC-004 | Neuralink has public customer, user, patient or usage signals. | partially verified medium | SRC-005SRC-006 |
| EC-005 | Neuralink's public GTM signals are visible but sales productivity is private. | partially verified medium | SRC-002 |
| EC-006 | Neuralink operates in a competitive market where differentiation requires private proof. | partially verified medium | SRC-002 |
| EC-007 | Neuralink shows active R&D/product development signals. | partially verified medium | SRC-003SRC-004SRC-007 |
| EC-008 | Neuralink's public team and hiring evidence is incomplete. | partially verified medium | SRC-007 |
| EC-009 | Neuralink's legal, regulatory, privacy and IP posture cannot be fully assessed from public sources. | partially verified medium | SRC-004SRC-005SRC-008 |
| EC-010 | No public source found in this run showed that Neuralink had IPO'd, been acquired or shut down. | partially verified medium | SRC-001SRC-002 |
| EC-011 | Core private diligence records for Neuralink are not publicly available. | not publicly verifiable high | SRC-001 |
| EC-012 | Neuralink has public momentum indicators, but they are not standalone proof of investment quality. | partially verified medium | SRC-002SRC-005 |
| ID | Publisher | Title | Accessed |
|---|---|---|---|
| SRC-001 | CB Insights | The Complete List Of Unicorn Companies | 2026-06-09 |
| SRC-002 | Neuralink | Neuralink home page | 2026-06-09 |
| SRC-003 | Neuralink | Neuralink technology page | 2026-06-09 |
| SRC-004 | Neuralink | Neuralink first-in-human clinical trial recruitment update | 2026-06-09 |
| SRC-005 | ClinicalTrials.gov / U.S. National Library of Medicine | NCT06429735 PRIME Study | 2026-06-09 |
| SRC-006 | Neuralink | Neuralink clinical trials and patient registry page | 2026-06-09 |
| SRC-007 | Neuralink | Neuralink careers page | 2026-06-09 |
| SRC-008 | Neuralink | Neuralink privacy policy | 2026-06-09 |
Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.